Phase 1 Study of MAR002 Given as Subcutaneous Injection in Healthy Men Aged 18 to 40

What this Trial Is About

Researchers are evaluating the safety and tolerability of MAR002, a drug given by subcutaneous injection, in healthy men aged 18 to 40 years. This phase 1 trial aims to understand how the body handles MAR002 and to monitor any treatment-emergent adverse events. The study focuses on healthy adult males, with measurements taken to assess the drugs pharmacokinetics and safety. Participants are assigned randomly to receive either different single doses Dose B, C, D, or E or multiple doses Dose F of MAR002, or a placebo, all given by subcutaneous injection. The study includes several cohorts, each receiving a specific dosing schedule. The trial uses a triple-blinded design to ensure objective results. During the study, participants will be monitored for adverse events and undergo pharmacokinetic assessments including drug concentration peaks, clearance, and half-life. Follow-up visits occur until Day 64 for early cohorts and Day 169 for later cohorts. The total duration depends on the assigned cohort schedule. Safety and drug behavior in the body are the primary focus throughout the study period.

Study of MAR002 in Healthy Men